{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:57:31Z","timestamp":1781643451671,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":19,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007102","name":"Zagazig University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007102","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is defined by chronic oxidative stress, hemolysis, vaso-occlusive crisis (VOC), endothelial injury, and end-organ damage. Paraoxonase1 (PON-1) serves a significant function as an anti-inflammatory and antioxidant agent. This study investigates PON1c.55L\u2009&gt;\u2009M and PON1c.192Q\u2009&gt;\u2009R polymorphism frequency in Egyptian children and adolescents with SCD, as well as the impact of these polymorphisms on PON-1 gene expression and enzymatic activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study recruited 70 SCD children in addition to 70 healthy matched participants as controls. Laboratory parameters, PON-1 gene molecular analysis, PON-1 gene expression, and enzymatic activity were investigated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PON-1 activity and expression were substantially reduced in patients with SCD than in controls (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001). We detected higher allelic frequencies of PON1c.192R (52.9% in SCD cases and 25.7% in controls). For\n                      <jats:italic>PON1<\/jats:italic>\n                      c.192Q\u2009&gt;\u2009R, compared with the genotype QQ, we found genotype QR, and RR were significantly associated with increased SCD risk.\n                    <\/jats:p>\n                    <jats:p>\n                      Alternatively, the PON1c.55L\u2009&gt;\u2009M variant allele had no significant association with SCD risk. Furthermore, SCD cases with the homozygote variant PON1c.192 RR, PON1c.55 MM genotypes exhibited decreased PON1 activity relative to controls possessing corresponding genotypes. SCD patients with the RR genotype in SCD exhibited notable reductions in RBC count, MCH, and MCHC, alongside substantial rises in WBCs, neutrophil count, LDH, ferritin, creatinine, cystatin C, and BUN levels. Additionally, substantial correlations were identified between the MM genotype variant and decreased RBC counts, alongside a notable increase in WBC count, serum ferritin, and cystatin C levels. A positive correlation between PON-1 activity and hematocrit (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u20090.26;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05) was identified in patients with SCD. Conversely, negative correlations were found with WBCs (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009-0.47;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001), creatinine (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009= \u2212\u200929;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05), cystatin C (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009= \u2212\u200937;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001) and ferritin levels (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009= \u2212\u20090.34;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The PON1c.55L\u2009&gt;\u2009M and PON 1c.192Q\u2009&gt;\u2009R gene polymorphisms in SCD cases influenced the PON-1 gene expression and activity. SCD cases with the variant PON1c.192 RR, PON1c.55 LL and MM genotypes exhibited downregulated PON1 activity. This reduction was correlated with elevated hemolysis and inflammation markers, ferritin levels, creatinine, cystatin C, and BUN levels, indicating a potential link between decreased PON1 activity and renal and cardiovascular dysfunction incidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12887-026-06597-w","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T03:15:49Z","timestamp":1774062949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of PON1 gene polymorphisms, paraoxonase 1 gene expression and activity in Egyptian children and adolescents with sickle cell disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Diana","family":"Hanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"I.Risha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"M.Eldaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hosnia","family":"Ragab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Mahmoud Hamed","family":"Sakr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Nafea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha Abdelaziz","family":"Noah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hala Mohammed Amin","family":"Abdelmoneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara F.","family":"Saadawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"6597_CR1","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/iub.584","volume":"64","author":"EN Chirico","year":"2012","unstructured":"Chirico EN, Pialoux V. Role of oxidative stress in the pathogenesis of sickle cell disease. IUBMB Life. 2012;64:72\u201380.","journal-title":"IUBMB Life"},{"issue":"7","key":"6597_CR2","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s11739-019-02160-x","volume":"14","author":"VM Pinto","year":"2019","unstructured":"Pinto VM, Balocco M, Quintino S, Forni GL. Sickle cell disease: a review for the internist. Intern Emerg Med. 2019;14(7):1051\u201364.","journal-title":"Intern Emerg Med"},{"key":"6597_CR3","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","volume":"387","author":"MT Gladwin","year":"2016","unstructured":"Gladwin MT. Cardiovascular complications and risk of death in sickle-cell disease. Lancet. 2016;387:2565\u201374.","journal-title":"Lancet"},{"key":"6597_CR4","first-page":"3647","volume":"120","author":"K Samir","year":"2018","unstructured":"Samir K, Gupta K, Adams-Graves PE. Sickle cell pain: a critical reappraisal. Blood. 2018;120:3647\u201357.","journal-title":"Blood"},{"issue":"5","key":"6597_CR5","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1159\/000540149","volume":"51","author":"JB Kunz","year":"2024","unstructured":"Kunz JB, Tagliaferri L. Sickle cell disease. Transfusion Medicine and Hemotherapy. 2024;51(5):332\u201344.","journal-title":"Transfusion Medicine and Hemotherapy"},{"key":"6597_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00041433-200008000-00007","volume":"11","author":"MI Mackness","year":"2000","unstructured":"Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol. 2000;11:383\u20138.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"6597_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.gene.2015.04.088","volume":"567","author":"M Mackness","year":"2015","unstructured":"Mackness M, Mackness B. Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles. Gene. 2015;567(1):12\u201321.","journal-title":"Gene"},{"issue":"7","key":"6597_CR8","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.arcmed.2019.02.002","volume":"49","author":"ME Moreno-God\u00ednez","year":"2018","unstructured":"Moreno-God\u00ednez ME, et al. Genotypes of common polymorphisms in the PON1 gene associated with paraoxonase activity as cardiovascular risk factor. Arch Med Res. 2018;49(7):486\u201396.","journal-title":"Arch Med Res"},{"issue":"1","key":"6597_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.atherosclerosis.2010.08.076","volume":"214","author":"LP Pr\u00e9court","year":"2011","unstructured":"Pr\u00e9court LP, Amre D, Denis AM, et al. The three-gen paraoxonase family: physiologic roles, actions and regulation. Atherosclerosis. 2011;214(1):20\u201336. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2010.08.076.","journal-title":"Atherosclerosis"},{"key":"6597_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00204-015-1579-5","volume":"90","author":"M Valko","year":"2016","unstructured":"Valko M, Jomova K, Rhodes CJ, Ku\u02c7ca K, Mus\u00edlek K. Redox- and non-redox-metal-induced formation of free radicals and their role in human disease. Arch Toxicol. 2016;90:1\u201337.","journal-title":"Arch Toxicol"},{"key":"6597_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3390\/antiox7100144","volume":"7","author":"S Tiainen","year":"2018","unstructured":"Tiainen S, Kiviniemi A, Hautala A, Huikuri H, Ukkola O, Tokola K, et al. Effects of a two-year home-based exercise training program on oxidized LDL and HDL lipids in coronary artery disease patients with and without Type-2 diabetes. Antioxidants. 2018;7:144.","journal-title":"Antioxidants"},{"issue":"12","key":"6597_CR12","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/j.freeradbiomed.2004.08.012","volume":"37","author":"R James","year":"2004","unstructured":"James R, Deakin S. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. Free Radic Biol Med. 2004;37(12):1986\u201394. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2004.08.012.","journal-title":"Free Radic Biol Med"},{"key":"6597_CR13","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.cbi.2016.04.005","volume":"259","author":"J Camps","year":"2016","unstructured":"Camps J, Garc\u00eda-Heredia A, Hern\u00e1ndez-Aguilera A, Joven J. Paraoxonases, mitochondrial dysfunction and non-communicable diseases. Chem-Biol Interact. 2016;259:382\u20137.","journal-title":"Chem-Biol Interact"},{"issue":"1","key":"6597_CR14","doi-asserted-by":"publisher","first-page":"7215","DOI":"10.1038\/s41598-023-34396-1","volume":"13","author":"JF Menezes","year":"2023","unstructured":"Menezes JF, Carvalho MO, Rocha LC, Dos Santos FM, Adorno EV, de Souza CC, et al. Role of paraoxonase 1 activity and PON1 gene polymorphisms in sickle cell disease. Sci Rep. 2023;13(1):7215.","journal-title":"Sci Rep"},{"key":"6597_CR15","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/S0953-6205(03)00041-4","volume":"14","author":"M Sent\u00ed","year":"2003","unstructured":"Sent\u00ed M, Tom\u00e1s M, Anglada R, Elosua R, Marrugat J, Covas MI, et al. Interrelationship of smoking, paraoxonase activity, and leisure time physical activity: a population-based study. Eur J Intern Med. 2003;14:178\u201384.","journal-title":"Eur J Intern Med"},{"key":"6597_CR16","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/cbf.1070","volume":"22","author":"B Agachan","year":"2004","unstructured":"Agachan B, Yilmaz H, Karaali Z, Isbir T. Paraoxonase 55 and 192 polymorphism and its relationship to serum paraoxonase activity and serum lipids in Turkish patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct. 2004;22:163\u20138.","journal-title":"Cell Biochem Funct"},{"key":"6597_CR17","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2^-\u0394\u0394CT method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"6597_CR18","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.jped.2013.09.005","volume":"90","author":"MK El-Ghamrawy","year":"2014","unstructured":"El-Ghamrawy MK, Hanna WM, Abdel-Salam A, El-Sonbaty MM, Youness ER, Adel A. Oxidant-antioxidant status in Egyptian children with sickle cell anemia: a single center based study. J Pediatr (Rio J). 2014;90:286\u201392.","journal-title":"J Pediatr (Rio J)"},{"issue":"8","key":"6597_CR19","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3390\/antiox8080252","volume":"8","author":"CO Reichert","year":"2019","unstructured":"Reichert CO, et al. Paraoxonases (PON) 1, 2, and 3 Polymorphisms and PON-1 Activities in Patients with Sickle Cell Disease. Antioxidants. 2019;8(8):252.","journal-title":"Antioxidants"},{"key":"6597_CR20","first-page":"11","volume":"20","author":"D Ray","year":"2007","unstructured":"Ray D, Deshmukh P, Goswami K, Garg N. Antioxidant vitamin levels in sickle cell disorders. Natl Med J India. 2007;20:11\u20133.","journal-title":"Natl Med J India"},{"key":"6597_CR21","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1194\/jlr.P028977","volume":"54","author":"N Martinelli","year":"2013","unstructured":"Martinelli N, Garc\u00eda-Heredia A, Roca H, Aranda N, Arija V, Mackness B, et al. Paraoxonase-1 status in patients with hereditary hemochromatosis. J Lipid Res. 2013;54:1484\u201392.","journal-title":"J Lipid Res"},{"issue":"2","key":"6597_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/00041433-199604000-00004","volume":"7","author":"MI Mackness","year":"1996","unstructured":"Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol. 1996;7(2):69\u201376.","journal-title":"Curr Opin Lipidol"},{"key":"6597_CR23","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1258\/ebm.2011.011090","volume":"236","author":"E Amengual-Cladera","year":"2011","unstructured":"Amengual-Cladera E, Nadal-Casellas A, G\u00f3mez-P\u00e9rez Y, Gomila I, Prieto RM, Proenza AM, et al. Phytotherapy in a rat model of hyperoxaluria: the antioxidant effects of quercetin involve serum paraoxonase 1 activation. Exp Biol Med (Maywood). 2011;236:1133\u20138.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"6597_CR24","first-page":"238","volume":"29","author":"I Szab\u00f3","year":"1991","unstructured":"Szab\u00f3 I, R\u00f3na K, Czinner A, Gach\u00e1lyi B. Human paraoxonase polymorphism: Hungarian population studies in children and adults. Int J Clin Pharmacol Ter Toxicol. 1991;29(6):238\u201341.","journal-title":"Int J Clin Pharmacol Ter Toxicol"},{"key":"6597_CR25","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1590\/S1415-47572005000100006","volume":"28","author":"NPC dos Santos","year":"2005","unstructured":"dos Santos NPC, Ribeiro-dos-Santos \u00c2K, Santos SE. Frequency of the Q192R and L55M polymorphisms of the human serum paraoxonase gene (PON1) in ten Amazonian Amerindian tribes. Genet Mol Biol. 2005;28:36\u20139.","journal-title":"Genet Mol Biol"},{"issue":"1","key":"6597_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.21608\/ajfm.2017.18282","volume":"28","author":"R Darwish","year":"2017","unstructured":"Darwish R, Megahed H, Attia M, El-Neily D. Paraoxonase 1 gene polymorphism and enzymatic activity as a prognostic marker in cases of poisoning by cholinesterase inhibitor pesticides among Egyptians. Ain Shams Journal of Forensic Medicine and Clinical Toxicology. 2017;28(1):88\u201398.","journal-title":"Ain Shams Journal of Forensic Medicine and Clinical Toxicology"},{"issue":"3","key":"6597_CR27","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bcmd.2011.01.002","volume":"46","author":"A Gizi","year":"2011","unstructured":"Gizi A, Papassotiriou I, Apostolakou F, Lazaropoulou C, Papastamataki M, Kanavaki I, et al. Assessment of oxidative stress in patients with sickle cell disease: The glutathione system and the oxidant\u2013antioxidant status. Blood Cells Mol Dis. 2011;46(3):220\u20135.","journal-title":"Blood Cells Mol Dis"},{"key":"6597_CR28","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood-2013-05-505016","volume":"122","author":"GJ Kato","year":"2013","unstructured":"Kato GJ, Nouraie SM, Gladwin MT. Lactate dehydrogenase and hemolysis in sickle cell disease. Blood. 2013;122:1091\u20132.","journal-title":"Blood"},{"key":"6597_CR29","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.bbagen.2011.07.014","volume":"1820","author":"P Brissot","year":"2012","unstructured":"Brissot P, Ropert M, Le Lan C, Lor\u00e9al O. Non-transferrin bound iron: a key role in iron overload and iron toxicity. Biochim Biophys Acta Gen Subj. 2012;1820:403\u201310.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"7","key":"6597_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/08880018.2021.1894280","volume":"38","author":"D Hanna","year":"2021","unstructured":"Hanna D, Beshir M, Khalifa N, Baz E, Elhewala A. Assessment of cystatin C in pediatric sickle cell disease and \u03b2-thalassemia as a marker of subclinical cardiovascular dysfunction: a case-control study. Pediatr Hematol Oncol. 2021;38(7):620\u201332. https:\/\/doi.org\/10.1080\/08880018.2021.1894280.","journal-title":"Pediatr Hematol Oncol"},{"key":"6597_CR31","first-page":"284","volume":"48","author":"AJ Delgado","year":"2003","unstructured":"Delgado AJ, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, et al. Antibodies to highdensity lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum. 2003;48:284\u201396.","journal-title":"Arthritis Rheum"},{"key":"6597_CR32","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1093\/joneph\/19.6.732","volume":"19","author":"TJ Kovacs","year":"2006","unstructured":"Kovacs TJ, Harris S, Vas TK, Seres I, Short CD, Wittmann IK, et al. Paraoxonase gene polymorphism and serum activity in progressive IgA nephropathy. J Nephrol. 2006;19:732\u20138.","journal-title":"J Nephrol"},{"issue":"15072","key":"6597_CR33","doi-asserted-by":"publisher","first-page":"1507277","DOI":"10.1155\/2016\/1507270","volume":"2016","author":"E Dounousi","year":"2016","unstructured":"Dounousi E, Bouba I, Spoto B, et al. A Genetic biomarke of oxidative stress, the paraoxonase-1 Q192R gene variant, associates with cardiomyopathy in CKD: a longitudinal study. Oxid Med Cell Longev. 2016;2016(15072):1507277. https:\/\/doi.org\/10.1155\/2016\/1507270.","journal-title":"Oxid Med Cell Longev"},{"key":"6597_CR34","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1177\/147323001204000431","volume":"40","author":"K Kotani","year":"2012","unstructured":"Kotani K, Tsuzaki K, Sakane N. Paraoxonase-1 gene Q192R polymorphism and reactive oxygen metabolites. J Int Med Res. 2012;40:1513\u20138.","journal-title":"J Int Med Res"},{"issue":"1","key":"6597_CR35","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1086\/301691","volume":"62","author":"JW Heinecke","year":"1998","unstructured":"Heinecke JW, Lusis AJ. Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet. 1998;62(1):20\u20134.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"6597_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/01.mol.0000174398.84185.0f","volume":"16","author":"M Aviram","year":"2005","unstructured":"Aviram M, Rosenblat M. Paraoxonases and cardiovascular diseases: pharmacological and nutritional influences. Curr Opin Lipidol. 2005;16(4):393\u20139. https:\/\/doi.org\/10.1097\/01.mol.0000174398.84185.0f.","journal-title":"Curr Opin Lipidol"},{"key":"6597_CR37","doi-asserted-by":"publisher","first-page":"108067","DOI":"10.1016\/jdiabres.2020.108067","volume":"161","author":"Y Shokri","year":"2020","unstructured":"Shokri Y, Variji A, Nosrati M, et al. Importance of paraoxonase 1 (PON1) as an antioxidant and antiatherogenic enzyme in the cardiovascular complications o type 2 diabetes: Genotypic and phenotypic evaluation. Diabetes Res Clin Pract. 2020;161:108067. https:\/\/doi.org\/10.1016\/jdiabres.2020.108067.","journal-title":"Diabetes Res Clin Pract"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-026-06597-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06597-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-026-06597-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:35:09Z","timestamp":1781642109000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12887-026-06597-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6597"],"URL":"https:\/\/doi.org\/10.1186\/s12887-026-06597-w","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all subjects involved in the study, Clinical trial number: not applicable.\u2019","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"284"}}